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Abstract
To reveal the clonal architecture of melanoma and associated driver mutations, whole genome sequencing (WGS) and
targeted extension sequencing were used to characterize 124 melanoma cases. Significantly mutated gene analysis using 13
WGS cases and 15 additional paired extension cases identified known melanoma genes such as BRAF, NRAS, and CDKN2A, as
well as a novel gene EPHA3, previously implicated in other cancer types. Extension studies using tumors from another 96
patients discovered a large number of truncation mutations in tumor suppressors (TP53 and RB1), protein phosphatases
(e.g., PTEN, PTPRB, PTPRD, and PTPRT), as well as chromatin remodeling genes (e.g., ASXL3, MLL2, and ARID2). Deep
sequencing of mutations revealed subclones in the majority of metastatic tumors from 13 WGS cases. Validated mutations
from 12 out of 13 WGS patients exhibited a predominant UV signature characterized by a high frequency of C-.T transitions
occurring at the 39 base of dipyrimidine sequences while one patient (MEL9) with a hypermutator phenotype lacked this
signature. Strikingly, a subclonal mutation signature analysis revealed that the founding clone in MEL9 exhibited UV
signature but the secondary clone did not, suggesting different mutational mechanisms for two clonal populations from the
same tumor. Further analysis of four metastases from different geographic locations in 2 melanoma cases revealed
phylogenetic relationships and highlighted the genetic alterations responsible for differential drug resistance among
metastatic tumors. Our study suggests that clonal evaluation is crucial for understanding tumor etiology and drug
resistance in melanoma.
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Introduction
The incidence of invasive melanoma in the United States in
2013 is estimated to be 76,690, with approximately 9,480 deaths
[1]. While the death rate due to melanoma is relatively low, and
many tumors are found at an early stage when they can be
completely resected and cured, the development of metastatic
disease is a harbinger of poor outcome. Though four new drugs
that prolong overall or progression-free survival were recently
approved for stage IV disease [2,3], the median survival for
metastatic melanoma remains poor. Work in the last decade has
identified a number of common and/or driver mutations in
melanoma and helped to elucidate the pathways determining
melanoma oncogenesis, proliferation, and metastasis. These
discoveries have led to the development of inhibitors for BRAF
and KIT (C-Kit) signaling, some of which have shown benefit in
melanoma patients [4,5].
The driver mutations in BRAF and NRAS that have been
identified cannot fully explain melanoma oncogenesis, as these
same mutations have been found at similar rates in benign nevi, or
moles [6,7]. These common, benign skin lesions infrequently
undergo malignant transformation into melanoma, but invariably
remain in their growth-arrested state. BRAF V600E-induced
oncogenic senescence has been implicated in melanoma cell cycle
arrest [8], together with loss of function of genes including TP53,
NF2, and IRF1 [9], CDKN2A (INK4A/ARF) and CDK4 [10]. In
fact, loss of senescence is an important process in RAS- and RAF-
induced transformation, implying that additional but still unknown
genomic changes must be involved in transformation to melano-
ma. The mutational variants identified by WGS can provide
insight into this process.
The first melanoma genome sequenced was derived from an
established cell line [11] and it showed a large number of SNVs,
most corresponding to a UV signature of C-.T transitions [12].
PLOS ONE | www.plosone.org 1 November 2014 | Volume 9 | Issue 11 | e111153
Recently, several exome-based studies have been conducted to
identify genes driving melanoma development. Directed sequenc-
ing has demonstrated ERBB4 mutations in melanomas [13] and
copy number analysis has revealed amplification of the histone
methyltransferase gene SETDB1 [14]. Frequent somatic muta-
tions in MAP3K5 and MAP3K9 were identified in metastatic
melanomas by exome sequencing [15]. A preliminary study of
matched whole exome sequencing of melanomas and matched
normals indicates that GRIN2A was frequently mutated in 14
specimens, and subsequent analysis of over 100 samples showed it
to be mutated in 33% of cases [16]. TRRAP and GRM3 were also
found to be mutated in a small proportion of tumors, indicating
that the glutamate pathway might play an important role in
melanoma development and progression [17]. Another exome
sequencing study described six novel melanoma genes: PPP6C,
RAC1, SNX31, TACC1, STK19, and ARID2 [18]. Recently,
PREX2, a phosphatidylinositol-3,4,5-trisphosphate-dependent
Rac exchange factor 2, was found to be mutated in 14% of 107
melanoma cases [19]. Whole genome sequencing of an acral
melanoma primary and lymph nodal metastasis showed 40 SNVs
in the primary, of which 39 were also present in the metastasis
[20].
Our analysis of 15 metastatic melanoma tumors from 13
patients shows very high numbers of non-synonymous SNVs and it
constitutes a useful catalogue of copy number alterations,
insertions, deletions and translocations within those genomes.
EPHA3 (ephrin type-A receptor 3) was found to be significantly
mutated in 28 melanoma cases. Extension analysis using 97
tumors from 96 patients revealed a number of truncation
mutations in well-known tumor suppressors, protein phosphatases,
as well as genes involved in chromatin remodeling. Notably, the
majority of these truncation mutations co-occur with BRAF and
NRAS mutations, suggesting a potential cooperating role during
the progression of melanoma. We also performed deep sequencing
of somatic mutations that uncovered the clonal structures of
melanomas, helped to dissect diverse mutational mechanisms in
subclones, and further established the initiation roles of BRAF and
NRAS mutations in melanoma. More importantly, our compar-
ative analysis of 4 metastases from different geographical locations
in 2 cases revealed a clonal evolution path and underscored the
genetic alterations responsible for drug resistance.
Results
Genomic analysis of the whole genome sequencing data
of 15 tumors from 13 melanoma cases
All 13 WGS patients, from whom 15 tumors and 13 sets of
normal PBMC were included in this study, had stage IV
melanoma. The metastatic samples were from diverse locations
including lung, chest wall, brain, lymph node, stomach, small
intestine, and adrenal gland (Figure 1). Using an Illumina paired-
end sequencing strategy, tumor and normal genomes were
sequenced to at least 29.5X-fold and 35X-fold haploid coverage,
respectively, with corresponding diploid coverage of 98.84% or
better based on concordance with SNP array data (Table S1 in
File S1). Candidate somatic changes were predicted using
multiple algorithms [21–25] and selected for hybridization
capture-based validation (Supplementary Materials and Methods).
We included capture probes corresponding to all putative somatic
single nucleotide variants (SNVs) and small insertions/deletions
(indels) that overlap with coding exons, splice sites, and RNA genes
(tier 1), a number of high-confidence SNVs and indels in non-
coding conserved or regulatory regions (tier 2), and non-repetitive
regions of the human genome (tier 3). In addition, we included
predicted somatic structural variants (SVs) genome-wide for
validation (Methods). Analysis of the high depth sequencing data
resulting from the captured target DNAs of 15 tumor and 13
normal samples (Table S2, S3 in File S1 and Supplementary
Materials and Methods in File S1) confirmed 17,361 tier 1 point
mutations, with a validation rate of 93.6%, 84 tier 1 indels, and
411 somatic SVs (Tables S4 and S5 in File S2). Seven of 15
tumors had over 1,000 tier 1 SNVs. This is among the highest
mutation frequency of known cancers. For comparison, AMLs
have a median of 13 tier 1 changes per genome [cite TCGA AML]
[26] and metastatic breast cancers have been reported with
between 32 (lobular) [27] and 50 (basal-like) [28]. C-.T
transitions were predominant in all 15 tumors, consistent with a
UV damage signature (Figure 1). Notably, MEL9, with 6,795
validated tier 1 point mutations (7.7-fold times the average
number from the other 12 cases), exhibited the highest C-.T
transition rate among 15 tumors. The patterns of point mutations
were very similar for the paired metachronous tumors from
patients 5 and 13 (Figure 1 and Table S6a in File S2).
Notably, we identified 443 tier 1 dinucleotide mutations in 13
WGS cases and among them, an average of 74% (ranging from
68% to 78%) are CC-.TT changes, consistent with previous
reports [11]. The ratio between dinucleotide and point mutations
in Tier 1 ranges from 0.76% to 6.28% while the ratio in Tiers 1–3
ranges from 0.46% to 2.43%, consistent with the higher GC
content in the coding sequences. (Table S7 in File S1)
We validated 84 coding small indels (65 deletions and 19
insertions) ranging from 1 to 37 base pairs (bp) in length, including
a complex frameshift indel (4 bp deletion and 2 bp insertion) in
TP53 and 1 bp deletions in STAG2 and CDKN2A (Table S5 in
File S2). We also identified a total of 411 validated rearrange-
ments for the 13 cases (range 10–87), including 240 deletions, 95
inversions, and 69 translocations (Table S5 in File S2). Across all
15 tumors, there was a median of 11 chromosomal rearrange-
ments disrupting protein-coding regions per tumor. Recurrent
deletions in tumor suppressor FHIT, the fragile histidine triad
gene, were identified in MEL5 and MEL10, while large deletions
interrupting CDKN2A were identified in 5 tumors from 4 patients
(MEL2, 5, 8, 9, and 10). Further, one 1 bp deletion and one
nonsense mutation in CDKN2A were identified in MEL3 and
MEL11, respectively. A deletion involving CTNNA2 was also
detected in MEL10. A focal amplification of CCND1 was
observed in MEL1 and MEL4, which resulted in increased
expression levels, according to DNA microarray analysis from
those tumors (data not shown). SVs and copy number alterations
for each of the 15 sequenced tumors are shown in Figure S1 in
File S1, providing a comprehensive view of genetic aberrations in
melanoma metastases.
Previous studies showed that TERT promoter mutations are
frequent in familial and sporadic melanoma [29,30] and other
cancer types [31]. We identified somatic mutations within the
promoter of TERT in 9 of 13 (68%) melanoma cases. Four distinct
somatic base substitutions were observed G.A, 101–146 bases
upstream of the TERT transcription start site (TSS). Three are
point mutations (C205T (MEL8), C228T (MEL4, 5, 10, 11), and
C250T (MEL1, 8, 9, 12)) and one is a dinucleotide mutation
(C242T, C243T (MEL13)) (Table S6b in File S2). Sequence
coverage levels achieved around the TERT promoter region
(500bp upstream from TSS) were low (,7.4X on average) due to
the sequence context (high GC) and repeat content. It is therefore
possible that the prevalence of TERT promoter mutation could be
higher than 68% in our sample set.
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Significantly mutated genes (SMG) and pathways in
melanoma
After our initial discovery using 13 WGS cases followed by the
validation analysis described above, we performed further
extension screening in 15 melanoma cases (25 metastatic tumors
and matched normal tissue; 6 cases with multiple metastases).
1,209 genes were chosen for screening based on our initial WGS
results and mutations and genes reported in several recent
genomic studies of melanoma (Tables S8a and S8b in File
S2) [13,15–18]. Using mutations identified in all 28 cases, we
performed MuSiC [32] analysis to discover genes displaying
significantly higher mutation rates than expected based on the
background mutation rate. A small group of genes was identified
as significant after applying a 5% false discovery rate threshold
(Table 1). This group included BRAF and NRAS, which were
found to be mutated in 18 and 4 patients of 28, respectively
(Figure 2). MEL9, the adrenal gland metastasis that was
hypermutated, harbored mutations in both BRAF (H574L) and
NRAS (Q61R); these two mutations were found to be present in
the same variant allele frequency cluster (see Subclonal architec-
ture in melanoma below). Meanwhile, mutations were not
detected in either BRAF or NRAS in MEL6, a lung metastasis,
and also four other tumors from the latter discovery group of 15
cases. The SMG list includes other genes known to be potentially
involved in cancer. For instance, protein tyrosine kinase EPHA3,
known mostly for its role in lung cancer [33], had 7 missense and 3
nonsense mutations, and tumor suppressor CDKN2A harbored
one splice site, one nonsense, and one frame-shift indel,
respectively (Figure 2). Mutations in a wide variety of protein
families were seen in this study, including a large number of non-
synonymous mutations in protein tyrosine phosphatases (e.g.,
PTPRB, PTPRT, and PTPN13), and protein tyrosine kinases
(e.g., EPHA7, EPHA3, KIT, FGFR4, FGFR1, and ROS1). Of
note, 8 missense and 1 nonsense mutations were found in ASXL3,
a member of the polycomb group. The existence of mutations in
glutamate receptors was described in prior exome sequencing
studies [16], and our data not only confirmed that GRIN2A was
mutated in melanoma (5 out of 28 cases) but also showed that
GRIN2B was recurrently mutated (Figure 2). In addition, a
number of mutations have also been found in other metabotropic
glutamate receptors, such as GRM1 and GRM3-8. Specifically,
out of 23 nonsynonymous mutations from GRM genes, one
nonsense and four missense mutations were from GRM3,
previously shown to harbor activating mutations in melanomas
[17]. The observed mutation rate was 0.22 to 143 mutations per
Mbp in the TCGA dataset compared to 3 to 155 mutations per
Mbp in our 15 whole genome sequenced samples. In addition to
the similar distribution of mutation rates, we also observed
recurrent single nucleotide variants including S225F and G394E
in EPHA7 and G114E and R136* in EPHA3 from both datasets.
The Comparison of the number of mutations in significant genes
between this study and TCGA report [34] is shown in Table S15
in File S1.
Melanomas harbor a number of aberrantly regulated signaling
pathways, including INK4A-CDK4/6-RB, ARF-TP53-MDM2,
RAS-RAF-MAPK, PTEN-PI3K-AKT, and aMSH-MC1R-
cAMP-MITF, all of which may be altered via genetic, genomic,
or epigenetic mechanisms [35,36]. Mutations and rearrangements
were identified in BRAF, NRAS, and several MAP kinases
including MAP3K1, MAP4K2, and MAP3K14 in the MAPK
signaling pathways; 24/28 patients had at least one mutation in
this pathway. In addition, 18 patients harbored somatic alterations
in genes affecting the RB/TP53 pathway, including CDKN2A,
CCND1, MDM2, and CDK2 (Figure 1 and Tables S9a, S9b,
and S9c in File S2). GRM3 and GRIN2A/2B alterations were
also frequently observed in the tumors sequenced herein,
suggesting the importance of glutamate mediated transduction in
melanoma (Figures 1 and 2).
Recurrence analysis using 96 additional melanoma cases
In addition to the 15 paired targeted samples, we also screened
1,209 genes using an extension set of 97 melanoma tumor samples
from 96 patients. Since matched normals are not available for
these 96 patients, we focused our analysis on known mutations and
truncation mutations. We identified 1,716 recurrent nonsynon-
ymous mutations found previously in our paired discovery
samples, in the COSMIC (Catalog of Somatic Mutations in
Cancer) database [37], or in recent melanoma studies (Table S10
in File S2) [13,15–18], as well as 1,287 truncation (nonsense,
splice site, and frame-shift) variants in 616 genes (Table S11 in
File S2). BRAF and NRAS mutations were identified in 60 and
19 patients, respectively. Additionally, three patients harbored
mutations in both BRAF and NRAS; 10 patients exhibited
dinucleotide polymorphisms (DNPs) in BRAF, and one DNP was
identified in NRAS. Further analysis revealed a number of
truncation mutations in well-established tumor suppressors (TP53
and RB1), protein phosphatase genes (e.g., PTEN, PTPRB,
PTPRD, PTPRN2, PTPRT, and PPP1R3A), and chromatin
remodeling genes (e.g., ASXL3, MLL2, and ARID2) (Figure S2
in File S1). In addition, three truncation variants (2 nonsense and 1
splice site) were found in the PREX2 gene, consistent with
previous findings (Figure S2 in File S1) [19]. Our analysis using
MuSiC [32] identified ASXL3 and PTPRT as harboring co-
occurring truncation mutations in our 96-patient extension set
(P = 0.002). All three patients containing a PREX2 truncation also
had an NRAS mutation (P= 0.008 for the co-occurence); none of
the three had a BRAF mutation (P = 0.062 for the mutual
exclusion between PREX2 and BRAF). ASXL3 truncations also
co-occurred with NRAS (P = 0.044). Interestingly, tumor suppres-
sors PTEN and RB1 co-occurred in our extension dataset
(P = 0.019), harboring six and four truncation events, respectively.
Subclonal architectures and driver mutations in
melanoma
We took hundreds of validated somatic mutations with read
depths of hundreds to thousands from capture validation and
applied the SciClone algorithm (https://github.com/genome/
sciclone) to cluster mutations with similar allelic fractions. These
clusters are indicative of distinct subclonal populations of tumor
cells. Multiple subclones were observed in the majority of 15 WGS
tumors (Table 2). Due to the high mutation rate and complex
copy number landscape in melanoma, the boundaries of some
clusters could not be clearly separated using genome-wide data.
We then selected ‘‘stable’’ genomic regions based on LOH and
CNV analyses using VarScan 2 [38] and used somatic mutations
Figure 1. Mutation pattern, spectrum, and clinical features in 15 metastases from 13 WGS melanoma cases. Mutations found in genes
from MAP kinase, PI3K-AKT, RB/TP53 pathways and glutamate receptors are shown. Copy number alterations and structural variants found in BRAF,
NRAS, TP53, CDKN2A/2B, and CCND1 are also displayed. The numbers and frequencies of tier 1 transition and transversion events identified in all 15
tumors are shown.
doi:10.1371/journal.pone.0111153.g001
Clonality and Mutations in Metastatic Melanomas
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from these regions for plotting (Figure 3 and Table S12a in
File S2). In MEL1, two distinct clusters at 36.7% and 21.7%
Variant Allele Frequency (VAF)s were identified. The majority of
mutations were from the 21.7% VAF cluster. MEL8 displayed a
similar pattern as MEL1, with one cluster at 37.8% VAF and
another cluster at 23.4%. The hypermutated MEL9 tumor has the
founding cluster at 46.8% VAF and the secondary but dominant
cluster centered at 19.8%, suggesting that a massive mutation
expansion took place in the 17.6% VAF cluster. Likewise, MEL10
had two clusters, centered at 30.6% and 19.5% VAFs respectively
(Figure 3). These estimates of tumor heterogeneity represent a
lower bound, and it is possible that additional subclone(s) were
present in these samples but not detected. Our results demonstrate
that melanoma is a disease characterized by significant intra-
tumor heterogeneity.
By associating mutations with specific subclonal populations, we
can infer the relative order in which these mutations were
acquired. 12 of 13 NRAS and BRAF mutations in the cohort are
clonal (or lie in copy number amplified regions), suggesting that
these mutations are involved in melanoma initiation (Figure 3
and Table 2). In MEL1, our analysis showed that CTNNB1
T41I missense (a highly recurrent site) maps to the founding clone
while KIT P157S (a novel mutation) resides in a subclone,
suggesting the former was an early event, while the latter may have
contributed to progression. Similarly, NRAS Q61K is present in
all cells of MEL8, suggesting an initiation role, while the ARID2
S1382F missense mutation is subclonal (Figure 3). MEL9 is
characterized by both NRAS and BRAF mutations in founding
clone, along with a CTNNB1 P16S mutation that arose later in
the evolution of the tumor.
Distinct mutational signatures in founding and
secondary clones of a hypermutated sample (MEL9)
It has been shown that DNA damage caused by UV light often
leads to the formation of covalent links between two adjacent
pyrimidine residues [11]. As a result, C-.T mutations in
melanoma samples often occur at dipyrimidine sequences. Our
analysis of 13 WGS melanoma cases showed that 12 cases had
greater than 89.9% of C-.T mutations occurring at the 39 base of
a pyrimidine dinucleotide, supporting previous findings [11].
However, MEL9, the hypermutated tumor, lacks this signature
and has only 59.5% C-.T occurring at the 39 base of a
dipyrimidine, comparable to 53% expected by chance (Figure 4).
We reasoned that the UV signature in MEL9 might be masked by
a large number of subsequent mutations arising from some other
mechanism. One candidate was that these mutations were the
result of a DNA repair defect (e.g., S418F and G1134R inMSH6,
G2569S in BRCA2, or G648E in ERCC6). To test this hypothesis,
we independently analyzed mutations from the founding and
subclonal populations described above. (Figure 4). Strikingly,
these two subclones in MEL9 exhibited two very distinct
phenotypes. The founding clone exhibited a classic UV-damage
phenotype with an abundance of C-.T transitions and a
disproportionately higher number of pyrimidine bases preceding
the mutated cytosine bases (Proportion test P= 1.60610210).
(Figure 4). In contrast, the subclone exhibited a typical pyrim-
idine base frequency preceding the mutated C base (59.5%,
P= 0.17); interestingly this subclone had a significantly higher
frequency of pyrimidine bases following the mutated C base
(P= 1.72610240), consistent with findings in another hypermu-
tated melanoma reported by Berger et al. [19]. Our hypothesis is
that UV-driven mutations in the originating, founding clone of
MEL9 damaged a DNA-repair gene and spurred a massive deficit
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occurring later than the UV damage, make up the lower-VAF
subclone. The mutation context observed in the secondary clone
of MEL9 does not match the patterns expected from defects in
MSH2 and MSH6, and it may be attributable to another repair
pathway. As a control, we also dissected the mutation spectrum in
the founding clone and subclone of MEL10. The subclone for
MEL10 also has a larger number of mutations, (Figure 4) but
both show a typical UV-signature, with a significant number of
Cytosine and Thymine bases preceding C-.T transition sites (P-
value for founding clone = 4.01610221, P-value for secondary
clone = 3.83610265).
Clonal and phylogenetic relationship among metastatic
tumors from different sites
Among the 28 paired cases, 8 (2 WGS and 6 extension cases)
had multiple metastasis samples, allowing the examination of
relationships of different tumors from the same individual. First,
we investigated the two WGS cases (MEL5 and MEL13) with two
metastasis samples each. The rearrangement and copy number
Figure 2. Mutation distribution in BRAF, NRAS, CDKN2A, EPHA3, GRIN2A, GRIN2B, PTPRT, and ASXL3. The locations of conserved protein
domains are highlighted. Each nonsynonymous substitution, splice site mutation, or indel is designated with a circle at the representative protein
position with color to indicate the translational effects of the mutation.
doi:10.1371/journal.pone.0111153.g002
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patterns were almost identical for the MEL13 paired metachro-
nous tumors from chest wall and lung (Figure 5). In MEL5, a
significant number of inversions on chromosome 3 were found to
be present in the pancreatic metastasis but not the lung metastasis
(Figure 5). Clonality analysis using point mutations from selected
copy number neutral regions revealed at least two clusters each in
the lung (22.2% and 14.3%) and pancreas (45.6% and 39.4%)
metastasis from MEL5 (Figure 6 and Table S12b–c in File
S2). The MEL5 lung metastasis has two distinct mutation clusters,
while the pancreas metastasis harbors two clusters with overlap-
ping boundaries. A comparison of genome-wide tier 1 mutations
in the pancreas versus lung metastases (Figure 6 and Table
Figure 3. Overview of subclonal landscape in melanoma (MEL1, 8, 9, and 10) and their associated driver mutations. Two plots are
shown for each case: kernel density (top), followed by the plot of tumor variant allele frequency by sequence depth for sites from selected copy
number neutral regions (see Methods). Data shown are from chromosomes 1, 3, 4, 6, 10, and 13 for MEL1, from chromosomes 1, 2, 5, 12, and 20 for
MEL8, from chromosomes 1, 3, 4, 6, 7, 12, and 13 for MEL9, and from chromosomes 6, 7, 10, 13, and 15 for MEL10. The data show evidence of two
clusters in MEL1, MEL8, MEL9 and MEL10 with the majority of mutations from the lower allele frequency clusters. Mutations detected in significantly
mutated genes in this study and genes implicated in Hodis et al. [18] were labeled.
doi:10.1371/journal.pone.0111153.g003
Clonality and Mutations in Metastatic Melanomas
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S12f in File S2) shows that greater than 99% of the tier 1
mutations (1127/1139) are shared between these two samples,
indicating they likely emerged from the same progenitor clone in
the primary tumor. Many MEL5 mutations appear to be enriched
in the pancreas sample. Additionally, a wider range of VAFs
present in the pancreas sample indicates that numerous copy
Figure 4. Dissecting mutational mechanisms using subclonal mutations. (a) Overall sequence context surrounding C-.T transitions in MEL9
and MEL10. (b) Density plots showing the founding clone and subclone in MEL9 and MEL10. (c) Mutation context analysis of the founding clones
detected a UV mutation signature in both MEL9 and MEL10. (d) Mutation context analysis of secondary clones detected a UV signature in MEL10 but
not MEL9.
doi:10.1371/journal.pone.0111153.g004
Clonality and Mutations in Metastatic Melanomas
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number altering events occurred after the initial development of
the pancreas metastasis. Both the lung and chest wall metastatic
tumors in MEL13 have a very similar clonal pattern (Figure 6
and Table S12d–e in File S2), with one dominant higher VAF
peak (24.9% and 32.4%, respectively) shouldered by less distinct
clusters of mutations. The slight difference in the peak VAFs of the
dominant clusters in these two metastases suggests that the chest
wall biological specimen has a higher purity (64.8% tumor) than
that of the lung metastasis (49.8% tumor). Consistent with the
kernel density plots (Figure 6), an analysis of VAFs of genome-
wide tier 1 mutations in MEL13 (Figure 6 and Table S12g in
File S2) shows similar clonal architecture in the two metastasis
samples, as most occur at comparable VAFs. Again, over 99% of
the mutations are shared between the two metastases (503 of 505)
in MEL13, with only 2 mutations being sample specific. This result
suggests that both MEL13 metastases are derived from the same
clone/subclone in the primary tumor.
Two cases (MEL167 and MEL174) with 4 synchronous
metastatic samples were sequenced with a targeted extension
panel. MEL167 has three tumor samples from small bowel and
one from a lymph node. The relative locations of small bowel
tumors 1, 2, and 3 from MEL167 are shown in Figure 7. Copy
number analysis using VarScan 2 shows that small bowel tumors 2
and 3 share amplifications on chromosomes 7q, 13q, and 20,
consistent with their close proximity in location. The lymph node
tumor shared amplifications on chromosomes 2 and 3 with small
bowel tumor 2 while small bowel tumor 1 showed no major
amplifications genome-wide (Figure 7). Phylip-based phyloge-
netics analysis (Supplementary Materials and Methods in File S1)
using mutations and their purity-corrected frequencies (Table
S13 In File S1 and Figure S3 in File S1) recapitulated the copy
number analysis-based findings and identified small bowel tumors
2 and 3 as closely related and most divergent from the normal.
The lymph node and small bowel tumor 1 are more similar to
each other and appear to be less divergent from the the normal
tissue (Figure 7). Mutations in TP53 (H179Y), NRAS (Q61K),
ATR (G2120C), and EPHA3 (P317S) are shared by all four
tumors, suggesting they are likely founding mutations from the
primary tumor (Figure 7 and Table S14 in File S2). On the
other hand, PREX2 (P614S) and ZNF831 (P1639S) are only
present in some tumors.
We also analyzed a quartet of synchronous tumors from
MEL174: two from the liver (liver tumors 1 and 2), one omentum
tumor, and one portal nodule tumor (Figure 8). Liver tumor 2
shows some similarities to the portal nodule tumor, with both
having major amplifications on chromosomes 7 and 8, while liver
tumor 1 and omentum tumor show a ‘‘quieter’’ overall copy
number landscape. Copy number alterations and mutation-based
phylogenetic largely agree on the relationship between these
tumors (Table S13 in File S1 and Figure S3 in File S1). Liver
tumor 1 and the omentum tumor responded to treatment with the
BRAF inhibitor vemurafinib, while the others continued growing/
progressing during treatment. We found that both BRAF (V600E)
and CTNNA2 (R755*) have much higher variant/mutant allele
frequencies in the non-reponsive portal nodule (BRAF: 65.2%;
CTNNA2: 15.6%) and liver tumor 2 (33.3%; 16.1%) than in the
omentum nodule (8.2%; 1.1%) and liver tumor 1(14.3%; 2.8%).
The CTNNA2 mutation is almost undetectable in the omentum
nodule with only one read, out of 94 total reads, supporting the
mutant allele. A MAP2K1 (E203K) mutation is only detected in
liver tumor 2 despite the high coverage (.40X) in all 4 metastases
(Table S14 in File S2). After applying purity-based VAF
adjustments, the portal nodule has the highest adjusted VAF at
72.47%, followed by liver tumor 2, liver tumor 1, omentum nodule
at 55.55%, 47.63%, and 41% respectively. Our data indicate that
sample-specific genetic alterations and variable frequencies of
mutations might contribute to differential treatment responses
among metastasis samples from the same patients, consistent with
a previous report [39] (Figure 8). Moreover, our analysis shows
that all four metastatic tumors from both patients were derived
from the same primary tumor but their patterns of mutations
diverged considerably during evolution and metastatic growth.
Discussion
This study represents a comprehensive whole genome and
targeted sequencing analysis of 124 human melanoma cases,
including 13 WGS, 15 paired targeted, and 96 unpaired targeted
extension cases. Besides the expected coding mutations in BRAF,
NRAS, CDKN2A, and other genes detected, significant numbers
of recurrent copy number variants and structural rearrangements
found in this analysis of 13 WGS cases suggest that they may be
important initiating and metastatic events in melanoma. Examples
include the amplification of CCND1 on chromosome 11 in two
patients, and CDKN2A deletions, which were observed in 5 of 13
patients, confirming previous data [40,41]. Our in silico signifi-
cance and proximity analysis of 28 paired cases (13 WGS and 15
targeted cases) identified known (e.g., BRAF, NRAS, CDKN2A,
and GRIN2A) and novel (e.g., EPHA3, GRIN2B, and ASXL3)
genes involved in melanoma (Table 1 and Figure 2). Moreover,
our extension analysis of 96 patients using targeted sequencing of
1,209 genes, revealed a number of truncation mutations in TP53,
RB1, PTEN, PTPRD, ARID2, ASXL3, and other genes co-
occuring with BRAF and NRAS mutations, suggesting their
cooperating roles during the progression of melanoma. These
alterations in other pathways, such as the PI3K pathway, may
partially explain the resistance of BRAF-mutant melanoma to
RAF inhibitors.
Previous melanoma whole genome [11,19,42] and whole exome
[18,43,44] studies have uncovered a complex landscape of
melanoma genomes including high mutation rate, a complex
copy number landscape, predominance of UV-related C.T
transitions, and frequent genetic alterations in well-known drivers
of melanomagenesis such as BRAF, NRAS, TP53, CDKN2A, and
PTEN, which was corroborated in our study.
As described, all 13 whole genome analyzed cases harbored
mutations or copy number alterations in either NRAS or BRAF
(with 1 tumor having both). Their presence largely in the founding
clone, as determined by VAF, is evidence of the contribution of
these genomic changes to melanoma initiation. Interestingly,
WGS of these tumors identified the mutations, copy number
alterations, and structural variants that occurred concomitantly
with these previously identified ‘‘driver’’ mutations. These findings
provide a mutational profile of melanoma metastasis against the
background of an initiating oncogenic event and point to genomic
changes that may be implicated in the loss of senescence and
oncogenic transformation in melanoma. In addition, the predom-
inance of C-.T transitions provides impressive evidence of UV-
related DNA damage in WGS metastatic tumors and suggests that
many of the potential driver SNVs were present long before the
spread of metastatic disease occurred. The sheer number of SNVs
in these tumors is striking, with one tumor possessing over 6,000
tier 1 mutations (,180 mutations per Mbp), and the average of
greater than 1,300 tier 1 SNVs per tumor constitutes a large
number by any metric.
In this study, we focused on subclone structures and intra-tumor
heterogeneity of melanoma, which was not addressed in previous
studies. Our results for 15 metastatic melanoma tumors demon-
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strate that melanoma is mainly a multi-clonal disease which
harbors diverse numbers of clonal populations with various
frequencies and densities. In contrast to point mutations, which
are likely the result of UV damage, the rate of structural variation
in this study was similar to that previously described for most
malignancies. Whole genome sequencing data herein indicate that
complex rearrangements may generate important gain- and loss-
of-function driver events in melanoma oncogenesis. Moreover,
many rearrangements may occur preferentially in genes that are
spatially localized together within transcriptional or chromatin
compartments, perhaps initiated by DNA strand breaks and
erroneous repair.
Subclone-specific mutation signature analysis in a hypermutator
sample (MEL9) revealed that the founding clone and the subclone
displayed a distinct mutation context, suggesting different muta-
tional mechanisms for two subclones from the same tumor. The
Figure 5. Comparison of Circos plots of the metastatic samples from two tissue sites of the same individuals (MEL5 and MEL13). In
MEL5, pancreas tumor specific structural variants (inversions and deletions) are clustered on chromosomes 2 and 5, and pancreas or lung enriched
rearrangements are drawn in yellow. In MEL13, highly similar copy number and structural variant patterns between lung and chest wall metastases
are shown. No purity-based copy number corrections were used for plotting copy number.
doi:10.1371/journal.pone.0111153.g005
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vast majority of mutations and re-arrangements were shared
between the two metastatic samples for both cases with
metachronous tumors, suggesting they are derived from the same
subclone(s) of the primary tumor. A significant number of
pancreas-specific inversions were identified in MEL5, though
their potential role in the progression of the disease is unclear.
Finally, in studying the clonal architecture of all WGS cases, we
confirmed that clonal heterogeneity is a common phenomenon in
melanoma and driver initiation and progression mutations are all
required for the development of melanoma. This suggests that
knowing the clonal architecture of each patient’s tumor will be
essential for understanding the evolutionary history of each tumor
and for formulating optimized treatment options. Importantly, our
phylogenetic study of two patients each with 4 different
synchronous metastases clearly revealed the complex relationships
among these tumors derived from the originating primary tumor
and suggest that melanoma therapy is a moving target and
constant monitoring of tumor genomes may be required to
develop an effective treatment plan as evidenced by the differential
response to Vemurafenib of 4 synchronous metastases from
MEL174.
Methods
Illumina library construction and sequencing
The procedure described by Mardis et al [45] was followed for
library construction and sequencing. Briefly, Illumina DNA
sequencing was used to generate between 117 and 286 million
base pairs of sequence data for each of the 15 metastatic tumors
and 13 matched normal samples, with haploid coverages ranging
from 29.51 to 63.22 (Table S1 in File S1). Comparison of
heterozygous SNPs detected in the whole genome sequencing
(WGS) data with SNPs array genotypes confirmed bi-allelic
detection of between 98.7 and 99.7% of the heterozygous array
SNPs in the 13 cases. Detailed coverage statistics for all cases are
included in Table S1 in File S1.
Mutation detection pipeline
For each sample, reads were aligned using BWA 0.5.9 (http://
sourceforge.net/projects/bio-bwa/) on a per-lane basis, merged
into a single bam file, and duplicate reads were removed using
Picard 1.29 (http://picard.sourceforge.net). Sample variants were
called using Samtools (svn rev 599) [23]. Somatic single nucleotide
variants were detected using SomaticSniper [25]. High quality
somatic predictions were defined as those sites with a SomaticSni-
Figure 6. Comparison of clonality patterns of metastatic samples from two tissue sites of the same individuals (MEL5 and MEL13).
Kernel density and variant allele frequency by sequence depth plots for each metastasis in MEL5 and MEL13. Data shown are from chromosomes 17,
18, and 21 for MEL5, and from chromosomes 3, 7, and 14 for MEL13. The plots indicate multiple clones in MEL5 with enrichment from lung to
pancreas in MEL5, and nearly identical clonal pattern in both metastases in MEL13.
doi:10.1371/journal.pone.0111153.g006
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per somatic score greater than 40 and an average mapping quality
greater than 40. Indels in all samples were called using a
combination of Pindel [22] and GATK [21]. Somatic variants were
grouped into tiers based on genome annotation as described
previously [45]. Y chromosome variants were filtered for all female
patients.
Structural variant detection
Structural variants (SVs) in all samples were predicted by
BreakDancer [24] and SquareDancer (https://github.com/
genome/gms-core/blob/master/lib/perl/Genome/Model/
Tools/Sv/SquareDancer.pl). All SV predictions were filtered
using TIGRA (Chen et al., in preparation) to identify assembled
breakpoints in SV flanking reads. The same procedure as
described in Ding et al. [26] for selecting somatic SVs was used.
6491 structural variants from the 13 WGS cases were sent for
capture validation
Validation of structural variants
All BWA-aligned capture reads and their mates that map within
1000 bp of the structural variant breakpoints were realigned by
CrossMatch (version 1.080721) to the assembled SV contigs and to
the reference. The threshold for an acceptable alignment is ,=1
unaligned base at either end, ,=1% substitutions, ,=1% indels
Figure 7. Phylogenetic and mutational relationships among four metastatic samples from different sites of the same individuals
(MEL 167). Geographic locations and CT scans of metastasis samples in MEL167 with three tumor samples from small bowel (mass 1, mass 2, and
mass 3) and one from mensenteric lymph node. Phylogenetic relationships, mutation patterns, and copy number landscape in all four tumors were
shown. Purity based VAF corrections were applied prior to phylogenetic analysis.
doi:10.1371/journal.pone.0111153.g007
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and a CrossMatch score .=50. An SV-supporting read is
required to span the breakpoint on the SV contig, align to 10 bases
of flanking on each side of the breakpoint, and have no alignment
to the reference above minimum alignment criteria. SV-support-
ing reads were tabulated in the tumor and normal sample
separately, and a Fisher’s Exact test was applied to these counts to
determine the somatic status of each variant. The same method for
determining SV-supporting reads was applied to the WGS
alignment data for those calls deemed somatic via all other
criteria. Variants with any SV-supporting reads in the normal
WGS sample were filtered out as potential germline variants or
alignment artifacts. An additional filter was put in place to filter
ALU sequences and the remaining high confidence SV events
were manually reviewed based on BWA mapping of supporting
capture validation data to the assembled SV contigs spanning the
breakpoint. 411 structural variants from the 13 WGS cases passed
the final manual review and filtering.
Kernel density analysis for identifying clusters and
estimating allele frequencies for each tumor
Tumor clonality estimates were determined using the mutation
allele frequencies from sites with deep coverage from capture
validation data. To minimize the effect of coverage on allele
frequency estimations, only mutations with .100x coverage in
both the normal and tumor validation data were included in this
analysis. Efforts were made to exclude somatic SNVs from regions
Figure 8. Phylogenetic and mutational relationships among four metastatic samples from different sites of the same individuals
(MEL 174). Geographic locations and CT scans of metastasis samples in MEL 174 with 2 samples from liver (liver tumor 1, liver tumor 2), one from
omentum, and one from portal nodule. Phylogenetic relationships among 4 metastatic tumors were shown. Purity based VAF corrections were
applied prior to phylogenetic analysis. Increased variant allele frequency of BRAF (V600E) in liver 2 and portal module, both tumors showed resistance
to vemurafinib treatment. BRAF amplifications were also shown in liver 2 and portal module tumors.
doi:10.1371/journal.pone.0111153.g008
Clonality and Mutations in Metastatic Melanomas
PLOS ONE | www.plosone.org 14 November 2014 | Volume 9 | Issue 11 | e111153
containing copy number alterations identified in WGS data.
Varscan 2 was utilized on whole-genome sequencing data to
eliminate all LOH SNV calls. For each chromosome, the variant
allele frequencies were plotted from both the tumor and normal
samples at sites where the normal sample’s variant allele frequency
fell between 40% and 60%. Chromosomes where variants
frequently exhibited highly variable variant allele frequencies in
the tumor sample were excluded from the clonality analysis. Thus
only a few diploid chromosomes were chosen to represent each
sample for this analysis. The remaining SNVs were further
segregated according to their segmented copy number states as
predicted by cnvHMM (states of copy number equal to 2, 3, or 4),
and each copy number state was analyzed individually. For each
copy number state in the tumor, a kernel density estimate (KDE)
plot was drawn for tumor variant allele frequencies using the
density function in R. A customized R function evaluated each
KDE plot to determine the number of significant peaks in variants
existing in the copy number neutral, or diploid regions. These
clusters thus identified served as an estimation of the number and
relative composition of clones and subclones present in each
tumor. Only copy number neutral data is presented in Figure 6.
Significantly mutated gene analysis
We used the SMG test in the MuSiC suite32, using the
particular options available for accommodating the large numbers
of somatic mutations discovered in some melanoma cases. The
SMG test identifies genes that have significantly higher somatic
and germline mutation rates than background. To account for
hypermutated samples, the ability to sub-group cases based upon
similarities in their overall mutation counts was utilized, and P-
values were calculated for mutated genes in each sub-group
independently. All P-values were combined using the same
methods as described in MuSiC suite32. For the purposes of this
analysis, MEL4, MEL6, and MEL9 was considered as a
hypermutant, with all other samples being placed in a separate
sub-group for the SMG analysis. For the analysis of significantly
mutated genes, genes not typically expressed in melanoma tumor
samples were filtered if they had an average RPKM#0.5. For the
RNA-seq based gene expression analysis, we used the Pancan12
per-sample log2-RSEM matrix from doi:10.7303/syn1734155.1.
A gene qualified as expressed if it had at least 3 reads in at least
70% of samples. For every gene, the average per-sample RNA-seq
by Expectation Maximization (RSEM) value was calculated across
TCGA SKCM samples from the same tumor-type.
Proximity analysis
Validated somatic mutations were identified that clustered
within specific protein regions across multiple individuals. This
was accomplished by querying the distance between amino acids
for every pair of mutations on a given transcript of a mutated gene
within the sample set, and then determined which mutations fell
within ‘‘close’’ proximity, where ‘‘close’’ was defined to be within a
limit of 10 amino acids. We used the MuSiC suite32 for the
proximity analysis.
Supporting Information
File S1 Supplementary Materials and Methods, along
with Supplementary Figures S1 to S4 and Supplementa-
ry Tables S1 to S3, S7, S13 and S15 and references cited
in the Supplementary materials and method section.
Figure S1 in File S1: Copy number patterns and structural
variants identified in all 15 tumors sequenced. Figure S2 in File
S1: Extension heatmap of recurrent BRAF and NRAS mutations
as well as truncation mutations in selected tumors suppressor,
protein phosphatase and chromatin remodeling genes. The
mutual exclusion and co-occurrence of common recurrent drivers
and truncation mutations are shown in the 96 extension cases.
Three melanoma cases harbored both BRAF and NRAS
mutations. Figure S3 in File S1: Density plots of variants to
estimate the purity of the four metastases for each patient MEL167
and MEL174. Both the density plots and the Scatter plots were
used for purity estimation of the metastases samples. Figure S4 in
File S1: Flowchart showing the detailed overview of the analysis
steps and the pipeline used for the analysis. Table S1 in File S1:
WGS haploid coverage and SNP array concordance. Haploid and
diploid coverage estimates are given for 15 whole-genome
sequenced samples. Haploid coverage is calculated as the amount
of non-redundant mapped read bases divided by the haploid size
of the human genome. Diploid coverage is estimated from the
fraction of heterozygous SNPs from high-density SNP array data
that were present in SAMtools raw (unfiltered) or filtered SNP
calls. Table S2 in File S1: Capture validation coverage. Custom
capture validation coverage of putative somatic mutations is
reported for the 13 cases in which such data were generated.
Shown are the fraction of bases targeted that were covered .1x,.
10x, and .20x in each sample. Table S3 in File S1: Tier 1–3
somatic SNVs predicted and validation rate. Numbers of validated
somatic SNVs in tiers 1, 2, and 3 are shown for the 13 cases having
both whole genome sequence data and custom capture validation.
Table S7 in File S1: Dinucleotide polymorphisms (DNP) in 13
WGS cases. Table S13 in File S1: Purity estimation of the multi-
metastases samples MEL167 and MEL174 using the density plots.
Table S15 in FileS1: Comparison of the number of Tier1 SNVs
in the TCGA melanoma dataset to the number of SNVs in the
WGS dataset.
(DOCX)
File S2 The Zipped file contains the Supplementary
Tables S4, S5, S6, S8, S9, S10, S11, S12, S14. Table S4 in
File S2: Validated somatic point mutations and indels: See
separate.xlsx file. Table S5 in File S2: Validated somatic
structural variants: See separate.xlsx file. Validated structural
variants in 15 whole genome sequenced samples are listed with
Patient ID, chromosomal positions of each breakpoint (A, B), the
type of event (DEL deletion, CTX translocation, INV inversion,
INS insertion, ITX tandem duplication), and the size of event in
bp. If a breakpoint is within a gene, the gene and transcript name
are given with the direction of transcription and transcript
substructure where the breakpoint is found (intron numbering is
relative to the first translat ed exon). Genes completely deleted are
listed in the final column. Table S6 in File S2: (a) Point
mutations, indels, structural variations, and copy number
variations presented in Figure 1. (b) TERT promoter mutations
identified in 13 WGS cases: See separate.xlsx file. Table S8 in
File S2: (a)Average haploid coverage across each targeted gene in
the extension experiment. (b) Extension discovery variant table (15
paired samples): See separate.xlsx file. Table S9 in File S2: (a)
Genes in the MAPK and Cell Cycle TP53/RB pathways. (b)
Nonsynonymous mutations in the MAPK pathway in 28 paired
discovery cases (c) Nonsynonymous mutations in the Cell Cycle
TP53/RB pathway in 28 paired discovery cases: See separate.xlsx
file. Table S10 in File S2: Extension analysis filtered variant
table (96 unpaired samples): See separate.xlsx file. Table S11 in
File S2: Extension analysis truncation mutation table (96
unpaired samples): See separate.xlsx file. Table S12 in File S2:
(a)Readcounts for point mutations pictured in Figure 5. (b)Read-
counts for point mutations pictured in Figure 6, MEL5 Lung
sample. (c) Readcounts for point mutations pictured in Figure 6,
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MEL5 Pancreas sample. (d) Readcounts for point mutations
pictured in Figure 6, MEL13 Lung sample. (e)Readcounts for
point mutations pictured in Figure 6, MEL13 Chest Wall
sample.(f) Readcounts for point mutations pictured in Figure 6,
MEL5 sample.(g) Readcounts for point mutations pictured in
Figure 6, MEL13 sample: See separate.xlsx file. Table S14 in
File S2: Nonsynonymous mutations in the four metastases
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